Dufour P, Maloisel F, Bergerat J P, Barats J C, Dellenbach P, Renaud R, Ritter P, Herbrecht R, Wendling C, Audhuy B
Dept Onco-Hematology, CHU de Hautepierre, Strasbourg, France.
Bull Cancer. 1991;78(3):273-80.
In June 1986 we initiated an intra-peritoneal (IP) mitoxantrone chemotherapy trial as consolidation treatment for ovarian carcinoma in CR or PR after induction therapy (surgery + CHAP combination chemotherapy). Thirty-two patients received 25 mg IP mitoxantrone every 3 wk for 6 months. The most frequent side-effects were abdominal pains; haematological toxicity was minimal. The response was assessed by third-look surgery. In group I patients (patients in histological complete remission at second-look surgery) 12 of 14 evaluable patients remained in CR at the time of third look. Ten of the 12 patients are still alive with no evidence of disease (NED) with a median follow-up of 9.7 months after completion of treatment. In group II patients (microscopic residual disease at second-look surgery), 7 of 9 evaluable patients entered in CR at the time of third look; 6 of the 7 are still alive with NED and with a median follow-up of 14.3 months. In 7 group III patients (macroscopic residual disease at the time of second look) no response to IP therapy was observed and all patients progressed. We conclude that IP mitoxantrone is a valuable consolidation treatment for patients in CR or with minimal residual disease; further follow-up is necessary to assess the impact on duration of remission and survival.
1986年6月，我们启动了一项腹腔内（IP）米托蒽醌化疗试验，作为诱导治疗（手术 + CHAP联合化疗）后处于完全缓解（CR）或部分缓解（PR）的卵巢癌患者的巩固治疗。32例患者每3周接受25 mg腹腔内米托蒽醌治疗，共6个月。最常见的副作用是腹痛；血液学毒性极小。通过再次探查手术评估疗效。在第一组患者（二次探查手术时组织学完全缓解的患者）中，14例可评估患者中有12例在第三次探查时仍处于CR状态。12例患者中有10例仍存活，无疾病证据（NED），治疗完成后的中位随访时间为9.7个月。在第二组患者（二次探查手术时有微小残留病灶）中，9例可评估患者中有7例在第三次探查时进入CR状态；7例中有6例仍存活且无疾病证据，中位随访时间为14.3个月。在7例第三组患者（二次探查时有肉眼可见残留病灶）中，未观察到对腹腔内治疗有反应，所有患者均病情进展。我们得出结论，腹腔内米托蒽醌是处于CR或残留病灶极少的患者的一种有价值的巩固治疗方法；需要进一步随访以评估对缓解期和生存期的影响。
